Global Neuromyelitis Optica Drug Market Size, Status and Forecast 2020-2026

Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.
Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.
In the last several years, global market of Neuromyelitis Optica Drug developed with the production growth rate about 4%. In 2015 global capacity of Neuromyelitis Optica Drug is more than 9100 K units.
Market Analysis and Insights: Global Neuromyelitis Optica Drug Market
In 2019, the global Neuromyelitis Optica Drug market size was US$ 34 million and it is expected to reach US$ 42 million by the end of 2026, with a CAGR of 3.0% during 2021-2026.
Global Neuromyelitis Optica Drug Scope and Market Size
Neuromyelitis Optica Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Neuromyelitis Optica Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Segment by Type, the Neuromyelitis Optica Drug market is segmented into Glucocorticoids, Immunotherapies, Other, etc.
Segment by Application, the Neuromyelitis Optica Drug market is segmented into Acute attack, Remission Prophylactic Treatment, etc.
Regional and Country-level Analysis
The Neuromyelitis Optica Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Neuromyelitis Optica Drug market report are North America, Europe, China, Japan, Southeast Asia, India and Central & South America, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of revenue for the period 2015-2026.

Competitive Landscape

and Neuromyelitis Optica Drug Market Share Analysis
Neuromyelitis Optica Drug market competitive landscape provides details and data information by vendors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by player for the period 2015-2020. Details included are company description, major business, company total revenue and the revenue generated in Neuromyelitis Optica Drug business, the date to enter into the Neuromyelitis Optica Drug market, Neuromyelitis Optica Drug product introduction, recent developments, etc.
The major vendors include Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP, etc.

This report focuses on the global Neuromyelitis Optica Drug status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Neuromyelitis Optica Drug development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study


Pfizer
Fresenius
Teva
Sandoz
Intas
Gyjtrs
NANG KUANG
Tianjin Kingyork
Baxter
CSL
Grifols
Octapharma
CBOP

Market segment by Type, the product can be split into


Glucocorticoids
Immunotherapies
Other

Market segment by Application, split into


Acute attack
Remission Prophylactic Treatment

Market segment by Regions/Countries, this report covers


North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:


To analyze global Neuromyelitis Optica Drug status, future forecast, growth opportunity, key market and key players.
To present the Neuromyelitis Optica Drug development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Neuromyelitis Optica Drug are as follows:
History Year: 2015-2019

Base Year:

2019

Estimated Year:

2020
Forecast Year 2020 to 2026
For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Frequently Asked Questions



This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.

  • By product type
  • By End User/Applications
  • By Technology
  • By Region

The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.

Please Select a Format

market Reports market Reports